AMRX - Amneal Pharmaceuticals, Inc.

QQQ $ 439.52 $ 0.00 (0 %)

DIA $ 388.40 $ 1.68 (0.43 %)

SPY $ 516.34 $ 5.28 (1.03 %)

TLT $ 90.16 $ 0.35 (0.39 %)

GLD $ 215.21 $ 2.24 (1.05 %)

Previous Close

$ 6.65

Open

$ 6.80

Bid

$ 0.00 x 0

Ask

$ 6.65 x 300

Day's Range

$ 6.56 - $ 6.82

52 Week Range

$ 1.74 - $ 6.90

Volume

1,788,120

Average Volume

Market Cap

1.17B

Beta (5Y Monthly)

$ 0.93

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-14-2024	12-31-2023	10-K
2	11-08-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-03-2023	12-31-2022	10-K
6	11-07-2022	09-30-2022	10-Q
7	08-08-2022	06-30-2022	10-Q
8	05-06-2022	03-31-2022	10-Q
9	03-01-2022	12-31-2021	10-K
10	11-08-2021	09-30-2021	10-Q
11	08-09-2021	06-30-2021	10-Q
12	05-07-2021	03-31-2021	10-Q
13	03-01-2021	12-31-2020	10-K
14	11-06-2020	09-30-2020	10-Q
15	08-06-2020	06-30-2020	10-Q
16	05-11-2020	03-31-2020	10-Q
17	03-02-2020	12-31-2019	10-K
18	11-07-2019	09-30-2019	10-Q
19	08-05-2019	06-30-2019	10-Q
20	05-09-2019	03-31-2019	10-Q
21	03-01-2019	12-31-2018	10-K
22	11-07-2018	09-30-2018	10-Q
23	08-09-2018	06-30-2018	10-Q
24	05-15-2018	03-31-2018	10-Q
25	03-09-2018	12-31-2017	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Assessing Amneal Pharmaceuticals: Insights...
05/06/2024 19:00:55

Goldman Sachs Maintains Buy on Amneal Phar...
05/06/2024 15:15:42

Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...

Truist Securities Reiterates Buy on Amneal...
05/06/2024 12:32:09

Truist Securities analyst Les Sulewski reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price targe...

generic-drugmaker-amneal-announces-over-270m-in-us-opioid-lawsuit-settlement

Generic Drugmaker Amneal Announces Over $2...
05/03/2024 18:43:45

Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 ear...

CORRECTION: Amneal Reaffirms 2024 Revenue ...
05/03/2024 18:09:08

Amneal Pharmaceuticals Q1 2024 Adj EPS $0....
05/03/2024 10:04:17

Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...

Amneal Announces FDA Approval Of Over-The-...
04/24/2024 12:12:36

Amneal Launches PEMRYDI RTU, The First Rea...
04/16/2024 12:16:46

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mes...

Bausch Health Announces Patent Lawsuit Aga...
04/05/2024 22:27:59

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announc...

Amneal Receives FDA Approval For Ciproflox...
03/25/2024 20:13:18

- Product references branded Ciprodex - Represents another complex, high value new product

FTC Files Amicus Brief in Asthma Inhaler P...
03/22/2024 17:56:54

-Wall Street Journal

Piper Sandler Maintains Overweight on Amne...
03/21/2024 18:06:47

Piper Sandler analyst David Amsellem maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price t...

Goldman Sachs Maintains Buy on Amneal Phar...
03/04/2024 14:20:36

Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...

why-is-generic-drug-focused-amneal-pharmaceuticals-stock-trading-lower-friday

Why Is Generic Drug-Focused Amneal Pharmac...
03/01/2024 15:57:45

Amneal Pharmaceuticals reveals Q4 2023 results with $616.98 million revenue, up 1% YoY. Despite an 8% drop in adjusted EBITDA, ...

Amneal Pharmaceuticals shares are trading ...
03/01/2024 11:58:27

Earnings Scheduled For March 1, 2024
03/01/2024 11:56:41

Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on rev...

Amneal Pharmaceuticals: Q4 Earnings Insights
03/01/2024 11:40:06

Amneal Expects Fiscal Year 2024 Adjusted E...
03/01/2024 11:09:47

Amneal Forecasts Fiscal Year 2024 Revenues...
03/01/2024 11:06:25

Amneal Pharmaceuticals Q4 Adjusted EPS $0....
03/01/2024 11:02:05

Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...